FDA lifts partial clinical suspension on Diamyd’s diabetes therapy trial

The US Food and Drug Administration (FDA) has lifted the partial clinical hold on the Phase III DIAGNODE-3 trial of Diamyd Medical’s antigen-specific immunotherapy Diamyd.

The Phase III trial has been designed to assess Diamyd’s safety and efficacy in patients who are recently diagnosed with type 1 diabetes.